Drugmakers raise US prices on over 250 medicines
NEW YORK CITY, New York: At the start of 2025, drug companies raised prices on over 250 brand-name medications in the U.S., including Pfizer's COVID-19 treatment Paxlovid, Bristol Myers Squibb's ...
Over 250 medicines to cost more from January 1 in the U.S; is your critical drug in the list? Check here
More than 250 medications, including Paxlovid and cancer therapies, will see price increases in the United States beginning ...
Deccan Chronicle6d
Expiry of Rs 12k cr patented US drugs a big opportunity for pharma
The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...
Pharmaceutical Technology9d
Ibrance by Pfizer for Renal Cell Carcinoma: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% phase transition success ...
Pharmaceutical Technology9d
Ibrance by Pfizer for Endometrial Cancer: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success ...
pharmaphorum13d
Ibrance trial failure dashes Pfizer’s growth hopes for the drug
Ibrance was first approved in 2015 as a treatment for breast cancer patients who had progressed after hormone therapy, and buoyed by expanded use as a first-line therapy has grown swiftly to reach ...
Press Gazette20d
Top 50 news websites in the world: AP and NBC see more than 50% monthly surge
President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...
precisionmedicineonline23d
Ibrance Plus Frontline Standard Therapy Delays Progression in HER2, HR-Positive Breast Cancer
SAN ANTONIO – Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) added to standard anti-HER2 and endocrine therapy may become a new standard of care for frontline maintenance treatment of hormone ...
Hosted on MSN25d
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
The early results presented before the San Antonio Breast Cancer Symposium saw an increased rate of progression-free survival ...
Yahoo Finance26d
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase III trial in patients with metastatic breast cancer. Unveiled ...
clinicaltrialsarena26d
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
Results found that IBRANCE was able to see medical profession free survival extended by an additional 15 months. Credit: Shutterstock / ShU studio Healthcare giant Pfizer’s IBRANCE (palbociclib) as a ...
Cancer Research26d
Palbociclib Dramatically Increases PFS in Metastatic Breast Cancer
The CDK4/6 inhibitor palbociclib (Ibrance; Pfizer) led to a significant improvement in progression-free survival (PFS) in patients with HR-positive, HER2-positive metastatic breast cancer when added ...